These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8032961)

  • 41. Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma.
    Casper ES; Schwartz GK; Sugarman A; Leung D; Brennan MF
    J Clin Oncol; 1997 May; 15(5):2111-7. PubMed ID: 9164225
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Cardiotoxicity due to prolonged administration of THP (2"R-4'-O-tetrahydropyranyl-adriamycin)].
    Suzuki M; Hirono M; Majima H
    Gan To Kagaku Ryoho; 1997 Oct; 24(13):1993-9. PubMed ID: 9350248
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
    Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
    Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
    Muggia FM; Hainsworth JD; Jeffers S; Miller P; Groshen S; Tan M; Roman L; Uziely B; Muderspach L; Garcia A; Burnett A; Greco FA; Morrow CP; Paradiso LJ; Liang LJ
    J Clin Oncol; 1997 Mar; 15(3):987-93. PubMed ID: 9060537
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase-II clinical trial of 4'-epi-doxorubicin in advanced solid tumors.
    Martoni A; Giovannini M; Tomasi L; Camaggi CM; Bellanova B; Monetti N; Rossini G; Tarquinii M; Martini A; Pannuti F
    Cancer Chemother Pharmacol; 1984; 12(3):179-82. PubMed ID: 6584236
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II study of esorubicin (4'deoxydoxorubicin) in anthracycline naive patients with ovarian cancer.
    Green MD; Speyer JL; Wernz JC; Colombo N; Beller U; Muggia FM; Beckman EM
    Invest New Drugs; 1990 Aug; 8(3):333-6. PubMed ID: 2272774
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pirarubicin in advanced breast cancer: a French cooperative phase II study.
    Spielmann M; Kerbrat P; Delozier T; Fumoleau P; Monnier A; Chevallier B; Bastit P; Namer M; Cattan A; Lucas P
    Eur J Cancer; 1990; 26(7):821-3. PubMed ID: 2145903
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II trial of carboplatin in patients with metastatic malignant melanoma. A report from the Eastern Cooperative Oncology Group.
    Chang A; Hunt M; Parkinson DR; Hochster H; Smith TJ
    Am J Clin Oncol; 1993 Apr; 16(2):152-5. PubMed ID: 8452109
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Esorubicin in advanced endometrial cancer: an ineffective and potentially toxic therapy. A Southwest Oncology Group study.
    Green JB; Green S; O'Toole RV; Alberts DS; Nahhas WA; Wallace DL
    Invest New Drugs; 1991 May; 9(2):191-3. PubMed ID: 1874602
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase II study of epirubicin in advanced adenocarcinoma of the pancreas.
    Wils J; Bleiberg H; Blijham G; Dalesio O; Duez N; Lacave A; Splinter T
    Eur J Cancer Clin Oncol; 1985 Feb; 21(2):191-4. PubMed ID: 3857181
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin.
    Unger C; Häring B; Medinger M; Drevs J; Steinbild S; Kratz F; Mross K
    Clin Cancer Res; 2007 Aug; 13(16):4858-66. PubMed ID: 17699865
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up.
    ; Chou HH; Wang KL; Chen CA; Wei LH; Lai CH; Hsieh CY; Yang YC; Twu NF; Chang TC; Yen MS
    Gynecol Oncol; 2006 Jun; 101(3):423-8. PubMed ID: 16325239
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II trial of combination chemotherapy for pancreatic cancer with 5-fluorouracil, mitomycin C, and hexamethylmelamine.
    Bruckner HW; Storch JA; Brown JC; Goldberg J; Chamberlin K
    Oncology; 1983; 40(3):165-9. PubMed ID: 6405338
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
    Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Esorubicin (4'-deoxydoxorubicin, NSC 267469) in advanced breast cancer. A phase II study of the CALGB.
    Muss HB; Van Echo D; Korzun AH; Henderson IC; Campbell T; Vogelzang NJ; Rice MA; Wood W
    Am J Clin Oncol; 1990 Jun; 13(3):233-7. PubMed ID: 2346128
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
    Schwartsmann G; Mans DR; Menke CH; Xavier N; Caleffi M; Ferreira Filho AF; Schunemann H; Kalakun L; Koya R; Pohlman P; Venegas LF
    Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):24-9. PubMed ID: 9144687
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.
    Bakker M; Droz JP; Hanauske AR; Verweij J; van Oosterom AT; Groen HJ; Pacciarini MA; Domenigoni L; van Weissenbruch F; Pianezzola E; de Vries EG
    Br J Cancer; 1998; 77(1):139-46. PubMed ID: 9459159
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study.
    Homesley HD; Blessing JA; Sorosky J; Reid G; Look KY
    Gynecol Oncol; 2005 Aug; 98(2):294-8. PubMed ID: 15975638
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis.
    Constantinidou A; Jones RL; Scurr M; Al-Muderis O; Judson I
    Eur J Cancer; 2009 Nov; 45(17):2930-4. PubMed ID: 19767198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.